NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta.

By F. Greten, M. C. Arkan, J. Bollrath, L. Hsu, Jason Goode, C. Miething, S. Göktuna, M. Neuenhahn, J. Fierer, Stephan A Paxian and 9 more. Cell, 2007

646 citations recorded by the source corpus.

Subfields: Cancer Research, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/a434f9fe2fe60d2aee6ebb0957a177de7e001c4e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. M. Hayden
2. S. Ghosh
3. Andrea Oeckinghaus
4. N. Perkins
5. M. Karin
6. Shao-Cong Sun
7. O. Maier
8. Roman Fischer

In Immunology

1. M. Hayden
2. S. Ghosh
3. Andrea Oeckinghaus
4. N. Perkins
5. Shao-Cong Sun
6. Shizuo Akira
7. M. Karin
8. Roman Fischer

In Oncology

1. M. Hayden
2. S. Ghosh
3. Andrea Oeckinghaus
4. Shao-Cong Sun
5. O. Maier
6. Roman Fischer

Citations in the corpus

• The inflammasome: an integrated view (2011, neutral): “matory phenotype with signs of high inflammasome activity in macrophages (132).”
• Is NF-κB a good target for cancer therapy? Hopes and pitfalls (2009, neutral): “However, one major pitfall that will have to be addressed before anti-IKK or NF-κB therapies can become successful is the surprising but pronounced ability of inhibitors of NF-κB activation to enhance the production of IL-1β and related cytokines owing to excessive inflammasome activation during bac”
• Immunity, Inflammation, and Cancer (2010, neutral): “However, prolonged NF-κB inhibition can result in a severe immune deficiency and may even lead to neutrophilia and greatly enhanced acute inflammation due to enhanced IL-1β secretion (Greten et al., 2007).”
• NF-κB, an Active Player in Human Cancers (2014, neutral): “The selective deletion in myeloid cells or the pharmacologic suppression of IKK2 in mice increased endotoxin susceptibility with elevated plasma IL-1 β levels (61).”